April 25, 2019 10:22 AM EDT

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration

Natalie Grover

Reporter

→ About two years after Biogen $BIIB walked away from Mitsubishi Tanabe Pharma‘s MT-1303 (amiselimod), the Japanese drugmaker has joined forces with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration

Natalie Grover

Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter Bio­gen ex­it, Mit­subishi Tan­abe Phar­ma links up with Sal­ix to de­vel­op amise­limod; Two drug de­vel­op­ers set up an­tibi­ot­ic col­lab­o­ra­tion

Natalie Grover

Reporter

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence